You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOmeprazole
Accession NumberDB00338  (APRD00446)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
Description

A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell.

Structure
Thumb
Synonyms
OMEP
OMP
OMZ
Prilosec
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-omeprazolecapsule (delayed release)20 mgoralAuro Pharma Inc2014-03-26Not applicableCanada
Auro-omeprazolecapsule (delayed release)10 mgoralAuro Pharma Inc2014-03-26Not applicableCanada
Ava-omeprazolecapsule (delayed release)20 mgoralAvanstra Inc2011-11-282014-08-21Canada
Bio-omeprazoletablet (delayed-release)20 mgoralBiomed PharmaNot applicableNot applicableCanada
Dom-omeprazole Drtablet (delayed-release)10 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-omeprazole Drtablet (delayed-release)20 mgoralDominion Pharmacal2013-01-23Not applicableCanada
Jamp-omeprazole Drtablet (delayed-release)20 mgoralJamp Pharma Corporation2014-02-11Not applicableCanada
Leader Omeprazoletablet, delayed release20 mg/1oralREMEDYREPACK INC.2013-06-04Not applicableUs
Losec 10 mgtablet (delayed-release)10 mgoralAstrazeneca Canada Inc1997-04-28Not applicableCanada
Losec 20 mgtablet (delayed-release)20 mgoralAstrazeneca Canada Inc1996-12-31Not applicableCanada
Losec Capsules 10mgcapsule (delayed release)10 mgoralAstrazeneca Canada Inc2000-10-032013-12-04Canada
Losec Capsules 20mgcapsule (delayed release)20 mgoralAstrazeneca Canada Inc1989-12-31Not applicableCanada
Losec Capsules 40mgcapsule (delayed release)40 mgoralAstrazeneca Canada Inc2003-10-172010-06-30Canada
Losec Mups - 10mgtablet (delayed-release)10 mgoralAstrazeneca Canada Inc2001-02-222009-12-01Canada
Losec Mups - 20mgtablet (delayed-release)20 mgoralAstrazeneca Canada Inc2001-02-222009-12-01Canada
Mylan-omeprazolecapsule (delayed release)20 mgoralMylan Pharmaceuticals Ulc2009-08-04Not applicableCanada
Mylan-omeprazolecapsule (delayed release)10 mgoralMylan Pharmaceuticals Ulc2009-08-04Not applicableCanada
Nat-omeprazole Drtablet (delayed-release)20 mgoralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Omeprazolecapsule (delayed release)10 mgoralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
Omeprazolecapsule (delayed release)20 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Omeprazolecapsule (delayed release)20 mgoralSanis Health Inc2010-06-16Not applicableCanada
Omeprazolecapsule (delayed release)20 mgoralPro Doc Limitee2010-02-05Not applicableCanada
Omeprazoletablet, delayed release20 mg/1oralREMEDYREPACK INC.2013-06-06Not applicableUs
Omeprazole Delayed-releasecapsule, delayed release40 mg/1oralRanbaxy Laboratories Inc.2008-07-25Not applicableUs
Omeprazole Magnesium Delayed Release Tabletstablet (delayed-release)20 mgoralDr Reddys Laboratories LtdNot applicableNot applicableCanada
Omeprazole Magnesium Delayed Release Tabletstablet (delayed-release)20 mgoralAccord Healthcare Inc2013-12-05Not applicableCanada
Omeprazole-20capsule (delayed release)20 mgoralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
PMS-omeprazolecapsule (delayed release)20 mgoralPharmascience Inc2009-03-13Not applicableCanada
PMS-omeprazolecapsule (delayed release)10 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-omeprazole Drtablet (delayed-release)20 mgoralPharmascience Inc2009-01-08Not applicableCanada
PMS-omeprazole Drtablet (delayed-release)10 mgoralPharmascience Inc2009-01-08Not applicableCanada
Priloseccapsule, delayed release10 mg/1oralAstra Zeneca Lp1995-11-15Not applicableUs
Priloseccapsule20 mg/1oralSTAT Rx USA LLC2009-09-30Not applicableUs
Priloseccapsule, delayed release40 mg/1oralAstra Zeneca Lp1998-06-08Not applicableUs
Priloseccapsule, delayed release20 mg/1oralAstra Zeneca Lp1990-10-01Not applicableUs
Prilosecgranule, delayed release2.5 mg/1oralAstra Zeneca Lp2002-02-09Not applicableUs
Prilosecgranule, delayed release10 mg/1oralAstra Zeneca Lp2002-02-09Not applicableUs
Priva-omeprazoletablet (delayed-release)20 mgoralPharmapar IncNot applicableNot applicableCanada
Q-omeprazolecapsule (delayed release)10 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-omeprazolecapsule (delayed release)20 mgoralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Ran-omeprazolecapsule (delayed release)20 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-12Not applicableCanada
Ran-omeprazoletablet (delayed-release)20 mgoralRanbaxy Pharmaceuticals Canada Inc.2011-11-29Not applicableCanada
Ratio-omeprazoletablet (delayed-release)20 mgoralTeva Canada Limited2005-01-24Not applicableCanada
Ratio-omeprazoletablet (delayed-release)10 mgoralTeva Canada Limited2005-01-24Not applicableCanada
Riva-omeprazole Drtablet (delayed-release)20 mgoralLaboratoire Riva Inc2013-07-25Not applicableCanada
Sandoz Omeprazolecapsule (delayed release)10 mgoralSandoz Canada Incorporated2007-09-14Not applicableCanada
Sandoz Omeprazoletablet (delayed-release)20 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Omeprazoletablet (delayed-release)10 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Omeprazolecapsule (delayed release)20 mgoralSandoz Canada Incorporated2007-09-14Not applicableCanada
Teva-omeprazoletablet (delayed-release)10 mgoralTeva Canada Limited2008-09-02Not applicableCanada
Teva-omeprazoletablet (delayed-release)20 mgoralTeva Canada Limited2008-09-02Not applicableCanada
Van-omeprazoletablet (delayed-release)20 mgoralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-omeprazolecapsule (delayed release)20 mgoralApotex Inc2004-01-28Not applicableCanada
Apo-omeprazolecapsule (delayed release)40 mgoralApotex IncNot applicableNot applicableCanada
Omeprazolecapsule, delayed release20 mg/1oralREMEDYREPACK INC.2013-03-06Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralClinical Solutions Wholesale2009-01-21Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralAltura Pharmaceuticals, Inc.2010-01-01Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralZydus Pharmaceuticals (USA) Inc.2012-11-23Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralSandoz Inc2003-01-28Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralAidarex Pharmaceuticals LLC2009-01-21Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-04-03Not applicableUs
Omeprazolecapsule20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-13Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralPhysicians Total Care, Inc.2009-01-23Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralAurobindo Pharma Limited2015-08-19Not applicableUs
Omeprazolecapsule, delayed release pellets20 mg/1oralActavis Pharma, Inc.2008-07-25Not applicableUs
Omeprazolecapsule, delayed release pellets40 mg/1oralReady Meds2008-07-25Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralGlenmark Pharmaceuticals Inc., Usa2014-10-31Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralBlenheim Pharmacal, Inc.2016-02-09Not applicableUs
Omeprazolecapsule, delayed release pellets40 mg/1oralKAISER FOUNDATION HOSPITALS2009-08-01Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralMajor Pharmaceuticals2010-07-16Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralSTAT Rx USA LLC2009-04-17Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralUnit Dose Services2003-11-11Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralCardinal Health2009-12-07Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralApotex Corp2003-11-11Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralProficient Rx LP2003-11-11Not applicableUs
Omeprazolecapsule, delayed release pellets20 mg/1oralContract Pharmacy Services Pa2010-03-09Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralPreferred Pharmaceuticals, Inc.2012-01-10Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralDr. Reddy's Laboratories Limited2014-03-01Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-22Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralRebel Distributors Corp.2003-09-03Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralSandoz Inc2003-01-28Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralAidarex Pharmaceuticals LLC2009-01-21Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralSafecor Health, LLC2014-09-30Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralClinical Solutions Wholesale2009-01-21Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2009-01-23Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralZydus Pharmaceuticals (USA) Inc.2012-11-23Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralREMEDYREPACK INC.2016-01-06Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-01-28Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralBlenheim Pharmacal, Inc.2015-03-10Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralSTAT Rx USA LLC2010-04-29Not applicableUs
Omeprazolecapsule40 mg/1oralUnit Dose Services2010-10-13Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralCardinal Health2011-01-14Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralGolden State Medical Supply2013-03-22Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralProficient Rx LP2003-11-11Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralDispensing Solutions, Inc.2012-12-12Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralPreferred Pharmaceuticals Inc2015-05-08Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralDr. Reddy's Laboratories Limited2014-03-01Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralSandoz Inc2009-01-21Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralAidarex Pharmaceuticals LLC2009-01-21Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralMedsource Pharmaceuticals2008-12-17Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralH.J. Harkins Company, Inc.2011-01-14Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralCitron Pharma LLC2015-08-19Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralREMEDYREPACK INC.2015-05-20Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2002-11-04Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralZydus Pharmaceuticals (USA) Inc.2012-11-23Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralMc Kesson Contract Packaging2003-01-28Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralMylan Pharmaceuticals Inc.2003-08-04Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralBlenheim Pharmacal, Inc.2015-02-25Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralRebel Distributors Corp2007-10-22Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralUnit Dose Services2002-11-04Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralCardinal Health2003-01-282016-03-15Us
Omeprazolecapsule, delayed release20 mg/1oralGolden State Medical Supply2013-03-22Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralKremers Urban Pharmaceuticals Inc.2009-01-23Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralCadila Healthcare Limited2012-11-23Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralPreferred Pharmaceuticals, Inc.2013-11-18Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralDr. Reddy's Laboratories Limited2014-03-01Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralSandoz Inc2003-01-28Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralREMEDYREPACK INC.2013-04-08Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralAphena Pharma Solutions Tennessee, Llc2009-01-23Not applicableUs
Omeprazolecapsule, delayed release pellets10 mg/1oralREMEDYREPACK INC.2013-02-112016-04-05Us
Omeprazolecapsule, delayed release20 mg/1oralCitron Pharma LLC2015-08-19Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralSt Marys Medical Park Pharmacy2013-08-08Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralbryant ranch prepack2009-01-21Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralAmerican Health Packaging2013-07-02Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralLife Line Home Care Services, Inc.2012-02-29Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralMylan Pharmaceuticals Inc.2009-01-22Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralBlenheim Pharmacal, Inc.2014-10-15Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralRebel Distributors Corp2007-10-22Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralAv Pak2011-07-11Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralCardinal Health2008-02-28Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralGolden State Medical Supply, Inc2015-01-06Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralKremers Urban Pharmaceuticals Inc.2002-11-04Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralCadila Healthcare Limited2012-11-23Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralLegacy Pharmaceutical Packaging2009-01-21Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralDr. Reddy's Laboratories Limited2009-01-21Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralSandoz Inc2003-01-28Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralREMEDYREPACK INC.2013-04-22Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralPd Rx Pharmaceuticals, Inc.2009-01-21Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-05Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralCitron Pharma LLC2015-08-19Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralApotex Corp2003-11-11Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralbryant ranch prepack2011-05-06Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralAmerican Health Packaging2009-12-07Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralMylan Pharmaceuticals Inc.2003-08-04Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralBlenheim Pharmacal, Inc.2013-09-30Not applicableUs
Omeprazolecapsule40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-13Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralAv Pak2011-07-11Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralCardinal Health2010-05-04Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralAurobindo Pharma Limited2015-08-19Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralKremers Urban Pharmaceuticals Inc.2003-09-03Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralCadila Healthcare Limited2012-11-23Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralLegacy Pharmaceutical Packaging2012-02-07Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralDr. Reddy's Laboratories Limited2009-01-21Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralPd Rx Pharmaceuticals, Inc.2009-01-21Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralPd Rx Pharmaceuticals, Inc.2002-11-04Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralApotex Corp2009-01-21Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralProficient Rx LP2014-10-31Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralAmerican Health Packaging2009-12-07Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralMidwest Drug Distribution, Inc.2015-02-04Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-01-28Not applicableUs
Omeprazolecapsule40 mg/1oralRebel Distributors Corp2010-10-13Not applicableUs
Omeprazolecapsule, delayed release pellets40 mg/1oralREMEDYREPACK INC.2013-02-152016-04-05Us
Omeprazolecapsule, delayed release20 mg/1oralPhysicians Total Care, Inc.2002-11-04Not applicableUs
Omeprazolecapsule20 mg/1oralNew Horizon Rx Group, LLC2013-12-31Not applicableUs
Omeprazolecapsule, delayed release pellets10 mg/1oralActavis Pharma, Inc.2008-07-25Not applicableUs
Omeprazolecapsule, delayed release pellets20 mg/1oralReady Meds2008-07-25Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralGlenmark Pharmaceuticals Inc., Usa2014-10-31Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralMajor Pharmaceuticals2008-02-28Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralRx Change Co.2003-11-11Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralKAISER FOUNDATION HOSPITALS2006-06-02Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralBlenheim Pharmacal, Inc.2013-09-30Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-01-14Not applicableUs
Omeprazolecapsule10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-12Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralPhysicians Total Care, Inc.2003-09-03Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralAurobindo Pharma Limited2015-08-19Not applicableUs
Omeprazolecapsule, delayed release pellets40 mg/1oralActavis Pharma, Inc.2008-07-25Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralTYA Pharmaceuticals2009-01-21Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralGlenmark Pharmaceuticals Inc., Usa2014-10-31Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralDr. Reddy's Laboratories Limited2009-01-21Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralPd Rx Pharmaceuticals, Inc.2003-11-11Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralMylan Institutional Inc.2003-09-01Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralCardinal Health2003-11-11Not applicableUs
Omeprazolecapsule, delayed release10 mg/1oralApotex Corp2003-11-11Not applicableUs
Omeprazolecapsule, delayed release40 mg/1oralProficient Rx LP2009-01-21Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralAphena Pharma Solutions Tennessee, Llc2002-11-04Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralPreferred Pharmaceuticals, Inc.2012-01-10Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralCarilion Materials Management2003-11-11Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-22Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralRebel Distributors Corp.2002-11-04Not applicableUs
Omeprazole Drcapsule, delayed release40 mg/1oralDIRECT RX2015-01-01Not applicableUs
Omeprazole Drcapsule, delayed release20 mg/1oralDIRECT RX2015-01-01Not applicableUs
Omeprazole Drcapsule, delayed release20 mg/1oralNorthwind Pharmaceuticals, LLC2014-10-27Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ahi-omeprazoletablet (delayed-release)20 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Being Well Omeprazoletablet, delayed release20 mg/1oralSave A Lot Food Stores Ltd2008-03-20Not applicableUs
Berkley and Jensen Omeprazoletablet, delayed release20 mg/1oralBJWC2008-02-28Not applicableUs
Care One Omeprazoletablet, delayed release20 mg/1oralAmerican Sales Company2008-02-29Not applicableUs
Dg Health Omeprazoletablet, delayed release20 mg/1oralDolgencorp, LLC2010-02-14Not applicableUs
Equaline Omeprazoletablet, delayed release20 mg/1oralSupervalu Inc2008-02-22Not applicableUs
Equate Omeprazolecapsule, delayed release20 mg/1oralWal Mart Stores Inc2015-09-02Not applicableUs
Equate Omeprazole Delayed Release Acid Reducertablet, delayed release20 mg/1oralWal Mart Stores Inc2008-02-27Not applicableUs
Exchange Select Omeprazoletablet, delayed release20 mg/1oralArmy & Air Force Exchange Service2008-10-28Not applicableUs
Family Wellness Omeprazoletablet, delayed release20 mg/1oralFamily Dollar Services Inc2013-08-14Not applicableUs
Formu Care Omeprazoletablet, delayed release20 mg/1oralAccess Business Group LLC2009-07-08Not applicableUs
Fulton Street Market Omeprazoletablet, delayed release20 mg/1oralAccess Business Group LLC2009-07-08Not applicableUs
Good Neighbor Pharmacy Omeprazolecapsule, delayed release20 mg/1oralAmerisource Bergen2015-03-25Not applicableUs
Good Neighbor Pharmacy Omeprazoletablet, delayed release20 mg/1oralAmerisource Bergen2008-02-27Not applicableUs
Good Sense Omeprazoletablet, delayed release20 mg/1oralL. Perrigo Company2008-02-28Not applicableUs
Harmon Face Values Omeprazoletablet, delayed release20 mg/1oralHarmon Stores Inc.2011-12-18Not applicableUs
Harris Teeter Omeprazoletablet, delayed release20 mg/1oralHarris Teeter, LLC2015-03-30Not applicableUs
Health Mart Omeprazoletablet, delayed release20 mg/1oralMc Kesson2012-03-20Not applicableUs
Healthy Accents Omeprazoletablet, delayed release20 mg/1oralDZA Brands LLC2008-03-03Not applicableUs
Heartburn Controlcapsule (delayed release)20 mgoralApotex Inc2015-03-12Not applicableCanada
Kirkland Signature Omeprazoletablet, delayed release20 mg/1oralCostco Wholesale Company2008-02-27Not applicableUs
Leader Omeprazoletablet, delayed release20 mg/1oralCardinal Health2008-02-28Not applicableUs
Members Mark Omeprazoletablet, delayed release20 mg/1oralSam's West Inc2008-02-25Not applicableUs
Novo-omeprazoletablet (delayed-release)20 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Olextablet (delayed-release)20 mgoralPendopharm Division Of De Pharmascience Inc2014-09-17Not applicableCanada
Omepcapsule (delayed release)20 mgoralSandoz Canada Incorporated2015-11-25Not applicableCanada
Omeprazoletablet, delayed release20 mg/1oralCVS Pharmacy2008-02-29Not applicableUs
Omeprazoletablet, delayed release20 mg/1oralPhysicians Total Care, Inc.2008-06-19Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralMeijer Distribution Inc2015-03-25Not applicableUs
Omeprazoletablet, delayed release20 mg/1oralSafeway2008-02-25Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralShopko Stores Operating Co., LLC2015-12-02Not applicableUs
Omeprazoletablet, delayed release20 mg/1oralRite Aid Corporation2008-02-25Not applicableUs
Omeprazoletablet, delayed release20 mg/1oralMajor Pharmaceuticals2008-02-29Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralRite Aid Corporation2015-03-26Not applicableUs
Omeprazoletablet, delayed release20 mg/1oralH E B2008-02-29Not applicableUs
Omeprazoletablet, delayed release20 mg/1oralGericare Pharmaceuticals2008-08-30Not applicableUs
Omeprazoletablet, delayed release20 mg/1oralWalgreen Company2008-02-27Not applicableUs
Omeprazoletablet, delayed release20 mg/1oralPerrigo New York Inc2008-02-25Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralH E B2015-04-03Not applicableUs
Omeprazoletablet, delayed release20 mg/1oralWestern Family Foods Inc2008-02-28Not applicableUs
Omeprazoletablet (delayed-release)20 mgoralLaboratoire Riva Inc2015-11-16Not applicableCanada
Omeprazoletablet, delayed release20 mg/1oralHy Vee Inc2008-03-02Not applicableUs
Omeprazoletablet, delayed release20 mg/1oralPublix Super Markets Inc2008-05-12Not applicableUs
Omeprazolecapsule, delayed release20 mg/1oralWalgreen Company2015-03-25Not applicableUs
Omeprazoletablet, delayed release20 mg/1oralKroger Company2008-02-25Not applicableUs
Omeprazoletablet (delayed-release)20 mgoralPharmascience Inc2015-10-08Not applicableCanada
Omeprazolecapsule, delayed release20 mg/1oralCVS Pharmacy2015-03-27Not applicableUs
Omeprazoletablet, delayed release20 mg/1oralMeijer Distribution Inc2008-02-29Not applicableUs
Omeprazoletablet, delayed release20 mg/1oralShopko Stores Operating Co., LLC2013-06-05Not applicableUs
Omeprazole 20 mgtablet (delayed-release)20 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Omeprazole Delayed Releasetablet, delayed release20 mg/1oralDexcel Ltd.2008-03-01Not applicableUs
Omeprazole Delayed Releasetablet, delayed release20 mg/1oralWeeks & Leo Co., Inc.2011-07-12Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20 mg/1oralTarget Corporation2011-05-19Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20 mg/1oralThe Kroger Co.2015-03-12Not applicableUs
Omeprazole Magnesiumcapsule20.6 mg/1oralBi Mart2015-11-25Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20 mg/1oralFreds2015-10-16Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20 mg/1oralFreds2015-10-16Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20 mg/1oralAlbertsons Companies2016-02-01Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20.6 mg/1oralGericare Pharmaceuticals2013-04-01Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20 mg/1oralWalgreens Company2015-09-01Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20 mg/1oralChain Drug Marketing Association2012-12-11Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20 mg/1oralHEB2015-07-01Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20 mg/1oralWal Mart Stores Inc2010-01-15Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20 mg/1oralMeijer Distribution Inc2014-09-22Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20 mg/1oralKaiser Permanente2011-05-21Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20 mg/1oralThe Kroger Co.2014-03-17Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20 mg/1oralDr. Reddy's Laboratories Limited2009-11-12Not applicableUs
Omeprazole Magnesiumcapsule, delayed release20 mg/1oralChain Drug Consortium, LLC2013-11-26Not applicableUs
Omeseccapsule, delayed release20 mg/1oralCorporacion Infarmasa2010-02-28Not applicableUs
Preferred Plus Omeprazoletablet, delayed release20 mg/1oralKinray2014-10-20Not applicableUs
Prilosec Otctablet, delayed release20 mg/1oralProcter & Gamble Manufacturing Company2012-08-15Not applicableUs
Prilosec Otctablet, delayed release20.6 mg/1oralProcter & Gamble Manufacturing Company2003-07-14Not applicableUs
Prilosec Otctablet, delayed release20.6 mg/1oralPhysicians Total Care, Inc.2005-05-23Not applicableUs
Quality Choice Omeprazoletablet, delayed release20 mg/1oralChain Drug Marketing Association2014-03-01Not applicableUs
Shoprite Omeprazoletablet, delayed release20 mg/1oralWakefern Food Corporation2013-08-06Not applicableUs
Signature Care Omeprazoletablet, delayed release20 mg/1oralSafeway2015-09-18Not applicableUs
Simply Right Omeprazoletablet, delayed release20 mg/1oralSam's West Inc2011-12-28Not applicableUs
Smart Sense Omeprazoletablet, delayed release20 mg/1oralKmart Corporation2011-01-20Not applicableUs
Sound Body Omeprazoletablet, delayed release20 mg/1oralBig Lots Stores, Inc.2015-08-17Not applicableUs
Sunmark Omeprazoletablet, delayed release20 mg/1oralMc Kesson2008-02-26Not applicableUs
Topcare Omeprazoletablet, delayed release20 mg/1oralTopco Associates LLC2008-02-29Not applicableUs
Topcare Omeprazole Delayed Releasecapsule, delayed release20 mg/1oralTopco Associates LLC2016-02-02Not applicableUs
Up and Up Omeprazoletablet, delayed release20 mg/1oralTarget Corporation2009-07-14Not applicableUs
Up and Up Omeprazolecapsule, delayed release20 mg/1oralTarget Corporation2015-04-17Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
AntraNot Available
AudazolNot Available
BelmazolNot Available
CeprandalNot Available
DanloxNot Available
DesecNot Available
ElgamNot Available
EmeprotonNot Available
GasecNot Available
GastrimutNot Available
GastrolocNot Available
IndurganNot Available
InhibitronNot Available
LogastricNot Available
LosecNot Available
MepralNot Available
MopralNot Available
OlexinNot Available
OmaprenNot Available
OmepralNot Available
OmeprazonNot Available
OmeprolNot Available
OmezolNot Available
OmisecNot Available
OmizacNot Available
OrtanolNot Available
ParizacNot Available
PrazidecNot Available
PrazolitNot Available
ProcelacNot Available
RamezolNot Available
RegulacidNot Available
SanamidolNot Available
UlceralNot Available
UlcesepNot Available
UltopNot Available
ZepralNot Available
Brand mixtures
NameLabellerIngredients
Omeclamox-pakPernix Therapeutics, LLC
Omeprazole and Sodium BicarbonatePar Pharmaceutical Inc.
Omeprazole/sodium BicarbonatePrasco Laboratories
ZegeridPhysicians Total Care, Inc.
Zegerid OtcBayer Health Care Llc
Salts
Name/CASStructureProperties
Omeprazole magnesium
Thumb
  • InChI Key: KWORUUGOSLYAGD-UHFFFAOYNA-N
  • Monoisotopic Mass: 712.198816192
  • Average Mass: 713.121
DBSALT000131
Omeprazole sodium
ThumbNot applicableDBSALT000857
Categories
UNIIKG60484QX9
CAS number73590-58-6
WeightAverage: 345.416
Monoisotopic: 345.114712179
Chemical FormulaC17H19N3O3S
InChI KeyInChIKey=SUBDBMMJDZJVOS-UHFFFAOYSA-N
InChI
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
IUPAC Name
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole
SMILES
COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassSulfinylbenzimidazoles
Direct ParentSulfinylbenzimidazoles
Alternative Parents
Substituents
  • Sulfinylbenzimidazole
  • Anisole
  • Methylpyridine
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Sulfoxide
  • Azacycle
  • Sulfinyl compound
  • Ether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationOmeprazole is indicated for the treatment of duodenal ulcers, benign gastric ulcers, gastroesophageal reflux disease (GERD), heartburn and other symptoms associated with GERD, erosive esophagitis, and long-term treatment of pathological hypersecretory conditions like Zollinger-Ellison syndrome, multiple endocrine adenomas, and systemic mastocytosis.
PharmacodynamicsAfter oral administration, the onset of the anti-secretory effect of omeprazole occurs within one hour and maximum effect occurring within two hours. At 24 hours, inhibition of secretion is approximately 50% of maximum and duration of inhibition lasts up to 72 hours. Although omeprazole has a very short plasma half-life, the anti-secretory effect lasts for a long time due to prolonged binding to parietal H+/K+ ATPase enzyme. When the drug has been discontinued, secretory activity will return to baseline over 3-5 days. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days. In studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion. Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date.
Mechanism of actionOmeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, omeprazole blocks the final step in acid production, thus reducing gastric acidity.
Related Articles
AbsorptionThe delayed-release capsule are enteric-coated (as omeprazole is acid-labile) so the absorption of omprazole begins once the granules leave the stomach. Absorption is rapid. Peak plasma levels occur within 0.5 - 3.5 hours. The absolute bioavailability (compared with intravenous administration) of the delayed-release capsule is 30-40% at doses of 20 - 40 mg, due to presystemic metabolism. This value increases slightly when given repeatedly. Based on a relative bioavailability study, the AUC and Cmax of PRILOSEC (omeprazole magnesium) for Delayed-Release Oral Suspension were 87% and 88% of those for PRILOSEC Delayed-Release Capsules, respectively. Interestingly, when the 40 mg delayed release capsule is given with or without applesauce, it is bioequivalent. However, when the 20 mg delayed release capsule is given with the same conditions, it is not bioequivalent. When the same capsule is given to the elderly, bioavailability increases. Omeprazole was 76% bioavailable.
Volume of distributionNot Available
Protein binding95% bound to human plasma protein.
Metabolism

Hepatic. Omeprazole is extensively metabolized by the cytochrome P450 (CYP) enzyme system. The two primary CYP isozymes involved are CYP2C19 and CYP3A4. Metabolism is stereoselective in which the S-isomer is converted to 5'O-desmethylomeprazole via CYP2C19. CYP3A4 converts the S-isomer to 3-hydroxyomeprazole. The R-isomer is converted to 5-hydroxyomeprazole by CYP2C19. CYP3A4 converts the R-isomer to any four different metabolites: 5-hydroxyomeprazole (5-OH OME), omeprazole sulfone (OME sulfone), 5'-O-desmethylomeprazole (5'-desmethyl OME), and 3-hydroxyomeprazole (3-OH OME).

SubstrateEnzymesProduct
Omeprazole
5-HydroxyomeprazoleDetails
Omeprazole
5'-O-Desmethyl omeprazoleDetails
Omeprazole
Omeprazole sulfoneDetails
Omeprazole
3-HydroxyomeprazoleDetails
Route of eliminationUrinary excretion is a primary route of excretion of omeprazole metabolites. Little, if any unchanged drug was excreted in the urine. The majority of the dose (about 77%) was eliminated in urine as at least six metabolites. Two were identified as hydroxyomeprazole and the corresponding carboxylic acid. The remainder of the dose was recovered in the feces.
Half life0.5-1 hour (healthy subjects, delayed-release capsule); 3 hours (hepatic impairment)
Clearance
  • 500 – 600 mL/min [Total body clearance, healthy subjects, delayed-release capsule]
  • 250 mL/min [Plasma clearance, Geriatric]
  • 70 mL/min [Plasma clearance, Hepatic Impairment]
ToxicitySymptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Omeprazole Action PathwayDrug actionSMP00226
Omeprazole Metabolism PathwayDrug metabolismSMP00613
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4244285 CYP2C19*2A Allele, homozygotePoor metabolizer, lower dose requirement, improved drug efficacy9867757
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4986893 CYP2C19*3A Allele, homozygotePoor metabolizer, lower dose requirement, improved drug efficacy9867757
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier-0.6326
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.5573
P-glycoprotein inhibitor IInhibitor0.6622
P-glycoprotein inhibitor IINon-inhibitor0.968
Renal organic cation transporterNon-inhibitor0.542
CYP450 2C9 substrateNon-substrate0.7838
CYP450 2D6 substrateSubstrate0.6175
CYP450 3A4 substrateSubstrate0.6901
CYP450 1A2 substrateInhibitor0.7505
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7895
Ames testNon AMES toxic0.5692
CarcinogenicityNon-carcinogens0.8318
BiodegradationNot ready biodegradable0.9778
Rat acute toxicity2.2254 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.719
hERG inhibition (predictor II)Non-inhibitor0.8977
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc
  • Dr reddys laboratories ltd
  • Impax laboratories inc
  • Kremers urban development co
  • Lek pharmaceuticals d d
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc florida
  • Astrazeneca lp
  • Dexcel pharma technologies ltd
  • Santarus, Inc.
Packagers
Dosage forms
FormRouteStrength
Capsule (delayed release)oral20 mg
Tablet, delayed releaseoral20 mg/1
Tablet (delayed-release)oral10 mg
Tablet (delayed-release)oral20 mg
Capsule (delayed release)oral40 mg
Kit
Capsuleoral10 mg/1
Capsuleoral40 mg/1
Capsule, delayed releaseoral10 mg/1
Capsule, delayed release pelletsoral10 mg/1
Capsule, delayed release pelletsoral20 mg/1
Capsule, delayed release pelletsoral40 mg/1
Capsuleoral
Capsuleoral20.6 mg/1
Capsule, delayed releaseoral20 mg/1
Capsule, delayed releaseoral20.6 mg/1
Capsuleoral20 mg/1
Capsule, delayed releaseoral40 mg/1
Granule, delayed releaseoral10 mg/1
Granule, delayed releaseoral2.5 mg/1
Tablet, delayed releaseoral20.6 mg/1
Capsule (delayed release)oral10 mg
Powder, for suspensionoral
Prices
Unit descriptionCostUnit
PriLOSEC 30 20 mg Delayed Release Capsule Bottle459.99USD bottle
Zegerid 30 20-1680 mg Packets Packet224.27USD packet
Zegerid 30 40-1680 mg Packets Packet224.27USD packet
PriLOSEC 30 10 mg Delayed Release Capsule Bottle174.37USD bottle
Omeprazole 28 20 mg Enteric Coated Tabs Box25.99USD box
PriLOSEC OTC 14 20 mg Enteric Coated Tabs Box19.99USD box
PriLOSEC 40 mg Delayed Release Capsule9.59USD capsule
Prilosec dr 40 mg capsule9.22USD capsule
Omeprazole 40 mg Delayed Release Capsule7.69USD capsule
Zegerid 40-1100 mg capsule7.48USD capsule
Zegerid 20 mg capsule7.19USD capsule
Zegerid 40 mg capsule6.46USD capsule
Prilosec dr 20 mg capsule6.24USD capsule
Prilosec 20 mg capsule dr6.15USD capsule
Prilosec dr 10 mg capsule5.59USD capsule
Omeprazole powder5.05USD g
Omeprazole 20 mg Delayed Release Capsule4.32USD capsule
Omeprazole 10 mg Delayed Release Capsule3.13USD capsule
Losec (Sustained-Release Tablet) 20 mg Capsule/Sustained Release Tablet2.48USD tablet
Losec (Sustained-Release Tablet) 10 mg Capsule/Sustained Release Tablet1.97USD tablet
Losec (Sustained-Release Capsule) 20 mg Capsule/Sustained Release Tablet1.24USD tablet
Apo-Omeprazole 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Mylan-Omeprazole 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Pms-Omeprazole (Delayed Release Tablet) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Pms-Omeprazole (Sustained-Release Capsule) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Ratio-Omeprazole (Sustained-Release Tablet) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Sandoz Omeprazole (Sustained-Release Capsule) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Mylan-Omeprazole 10 mg Capsule/Sustained Release Tablet0.86USD tablet
Sandoz Omeprazole (Sustained-Release Capsule) 10 mg Capsule/Sustained Release Tablet0.86USD tablet
Zegerid otc 20-1100 mg capsule0.78USD capsule
Prilosec otc 20 mg tablet0.76USD tablet
Omeprazole dr 20 mg tablet0.66USD tablet
CVS Pharmacy omeprazole dr 20 mg tablet0.53USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1338377 No1996-06-112013-06-11Canada
CA2180535 No2004-03-232014-01-05Canada
US5690960 No1994-11-252014-11-25Us
US5817338 No1995-10-062015-10-06Us
US5840737 No1996-07-152016-07-15Us
US5900424 No1996-05-042016-05-04Us
US6147103 Yes1999-04-092019-04-09Us
US6150380 Yes1999-05-102019-05-10Us
US6166213 Yes1999-04-092019-04-09Us
US6191148 Yes1999-04-092019-04-09Us
US6403616 No1999-11-152019-11-15Us
US6428810 No1999-11-032019-11-03Us
US6489346 No1996-07-162016-07-16Us
US6645988 No1996-07-162016-07-16Us
US6699885 No1996-07-162016-07-16Us
US6780882 No1996-07-152016-07-15Us
US7399772 No1996-07-152016-07-15Us
US9023391 No2005-08-162025-08-16Us
USRE45198 No1996-07-162016-07-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point155 °CFDA label
water solubilityVery slightly soluble FDA label
logP2.23SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.359 mg/mLALOGPS
logP1.66ALOGPS
logP2.43ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)9.29ChemAxon
pKa (Strongest Basic)4.77ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area77.1 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity93.66 m3·mol-1ChemAxon
Polarizability37.45 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Arne E. Brandstrom, Bo R. Lamm, “Processes for the preparation of omeprazole and intermediates therefore.” U.S. Patent US4620008, issued October, 1982.

US4620008
General References
  1. Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006 Dec 27;296(24):2947-53. [PubMed:17190895 ]
External Links
ATC CodesA02BC01A02BD01A02BD05
AHFS Codes
  • 56:28.36
PDB EntriesNot Available
FDA labelDownload (218 KB)
MSDSDownload (73.8 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Omeprazole.
Alendronic acidThe therapeutic efficacy of Alendronate can be decreased when used in combination with Omeprazole.
AmphetamineOmeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Omeprazole.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Omeprazole.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Omeprazole.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Omeprazole.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Omeprazole.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Omeprazole.
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Omeprazole.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Omeprazole.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Omeprazole.
ClodronateThe therapeutic efficacy of Clodronate can be decreased when used in combination with Omeprazole.
ClopidogrelOmeprazole may decrease the antiplatelet activities of Clopidogrel.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Omeprazole.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Omeprazole.
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Omeprazole.
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Omeprazole resulting in a loss in efficacy.
DabrafenibThe serum concentration of Omeprazole can be decreased when it is combined with Dabrafenib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Omeprazole.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Omeprazole.
DexmethylphenidateOmeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextroamphetamineOmeprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Omeprazole.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Omeprazole.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Omeprazole.
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Omeprazole.
FluconazoleThe serum concentration of Omeprazole can be increased when it is combined with Fluconazole.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Omeprazole.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Omeprazole.
IbandronateThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Omeprazole.
Iron DextranOmeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Omeprazole.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Omeprazole.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Omeprazole.
LumacaftorThe serum concentration of Omeprazole can be decreased when it is combined with Lumacaftor.
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Omeprazole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Omeprazole.
MethylphenidateOmeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Omeprazole.
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Omeprazole.
NelfinavirThe serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Omeprazole resulting in a loss in efficacy.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Omeprazole.
PamidronateThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Omeprazole.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Omeprazole.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Omeprazole.
PhenytoinThe serum concentration of Omeprazole can be decreased when it is combined with Phenytoin.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Omeprazole.
RaltegravirThe serum concentration of Raltegravir can be increased when it is combined with Omeprazole.
RifampicinThe serum concentration of Omeprazole can be decreased when it is combined with Rifampicin.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Omeprazole.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Omeprazole.
RisedronateThe therapeutic efficacy of Risedronate can be decreased when used in combination with Omeprazole.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Omeprazole.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Omeprazole.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Omeprazole.
St. John's WortThe serum concentration of Omeprazole can be decreased when it is combined with St. John's Wort.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Omeprazole.
TiludronateThe therapeutic efficacy of Tiludronate can be decreased when used in combination with Omeprazole.
TipranavirThe serum concentration of Omeprazole can be decreased when it is combined with Tipranavir.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Omeprazole.
VoriconazoleThe serum concentration of Omeprazole can be increased when it is combined with Voriconazole.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Omeprazole.
Zoledronic acidThe therapeutic efficacy of Zoledronate can be decreased when used in combination with Omeprazole.
Food Interactions
  • Avoid alcohol.
  • Take 30-60 minutes before meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium-exchanging atpase activity
Specific Function:
Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name:
ATP4A
Uniprot ID:
P20648
Molecular Weight:
114117.74 Da
References
  1. Tajima A, Koizumi K, Suzuki K, Higashi N, Takahashi M, Shimada T, Terano A, Hiraishi H, Kuwayama H: Proton pump inhibitors and recurrent bleeding in peptic ulcer disease. J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S237-41. doi: 10.1111/j.1440-1746.2008.05557.x. [PubMed:19120905 ]
  2. Shi S, Klotz U: Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008 Oct;64(10):935-51. doi: 10.1007/s00228-008-0538-y. Epub 2008 Aug 5. [PubMed:18679668 ]
  3. Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmoller J: Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009 Jan;65(1):19-31. doi: 10.1007/s00228-008-0576-5. Epub 2008 Oct 17. [PubMed:18925391 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Foti RS, Wahlstrom JL: CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos. 2008 Mar;36(3):523-8. Epub 2007 Nov 29. [PubMed:18048485 ]
  2. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [PubMed:15258107 ]
  3. Li XQ, Weidolf L, Simonsson R, Andersson TB: Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther. 2005 Nov;315(2):777-87. Epub 2005 Aug 10. [PubMed:16093273 ]
  4. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T: Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997 Nov;283(2):434-42. [PubMed:9353355 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Li XQ, Weidolf L, Simonsson R, Andersson TB: Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther. 2005 Nov;315(2):777-87. Epub 2005 Aug 10. [PubMed:16093273 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK: Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120-6. [PubMed:8423765 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Turpeinen M, Uusitalo J, Jalonen J, Pelkonen O: Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci. 2005 Jan;24(1):123-32. [PubMed:15626586 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name:
CYP11A1
Uniprot ID:
P05108
Molecular Weight:
60101.87 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Hitzl M, Klein K, Zanger UM, Fritz P, Nussler AK, Neuhaus P, Fromm MF: Influence of omeprazole on multidrug resistance protein 3 expression in human liver. J Pharmacol Exp Ther. 2003 Feb;304(2):524-30. [PubMed:12538803 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7. [PubMed:11770010 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11. [PubMed:15313923 ]
  2. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [PubMed:19076159 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on July 27, 2016 03:12